
Rigel Pharmaceuticals RIGL
$ 29.2
0.03%
Quarterly report 2026-Q1
added 05-05-2026
Rigel Pharmaceuticals DPO Ratio 2011-2026 | RIGL
Annual DPO Ratio Rigel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.9 | 103 | 761 | 2.74 K | 1.26 K | 1.6 K | 1.67 K | 8.13 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.13 K | 97.9 | 2.05 K |
Quarterly DPO Ratio Rigel Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.5 | 107 | 114 | 80.4 | 56.5 | 250 | 389 | 476 | 490 | 1.35 K | - | 497 | 203 | 3.17 K | - | 1.46 K | 2.4 K | 1.27 K | - | 2.42 K | 1.21 K | 2.31 K | - | 1.22 K | 1.22 K | 4.5 K | - | 8.45 K | 19.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.4 K | 56.5 | 2.22 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
74.3 | $ 33.24 | -5.01 % | $ 894 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | ||
|
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.75 | 6.06 % | $ 466 M | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
91.4 | $ 0.88 | 1.24 % | $ 147 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
82.7 | $ 2.84 | 8.81 % | $ 265 M | ||
|
Anika Therapeutics
ANIK
|
43.4 | $ 14.85 | -1.17 % | $ 213 M | ||
|
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | ||
|
Incyte Corporation
INCY
|
200 | $ 97.05 | -0.37 % | $ 18.9 B | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
Ionis Pharmaceuticals
IONS
|
815 | $ 75.54 | -0.32 % | $ 12.1 B | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
Coherus BioSciences
CHRS
|
507 | $ 1.64 | 4.14 % | $ 192 M | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Arcutis Biotherapeutics
ARQT
|
133 | $ 20.78 | -1.09 % | $ 2.64 B |